Safety, Tolerability and Gut microbIota AnalysiS of an Oral Microbiotherapy in Amyotrophic Lateral Sclerosis; an Open-label Phase 1b Pilot Trial
Latest Information Update: 19 May 2025
At a glance
- Drugs MaaT 033 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms IASO
- Sponsors MaaT Pharma
Most Recent Events
- 12 May 2025 According to MaaT Pharma media release, an external Scientific Advisory Committee took place at the end of March 2025 to review the full data. The Scientific Advisory Committee provided insights regarding the best population to target in a Phase 2 trial.
- 12 May 2025 Final data readout results were presented in a MaaT Pharma media release.
- 26 Nov 2024 According to MaaT Pharma media release, a total of 15 participants across two centers in France have been enrolled in the Phase 1 trial.